Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: David L. Hachey who wrote (18435)	4/1/1998 12:36:00 PM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

David, It's a pleasant surprise to learn that practicing scientists are willing to wade through the pseudo- babble most of us stock jockeys deposit on this thread. Thanks for volunteering to inform the astute afficionados. Hopefully, they will then interpret it for the rest of us. Please keep posting.

To: David L. Hachey who wrote (18435)	4/1/1998 1:53:00 PM
From: tuck	Read Replies (1) \| Respond to of 32384

David, Ligand may want to keep their numbers to themselves for the time being. But there may be some papers accompanying Phase I/II trials that mention the spike in numbers, and whether or not a meal was part of the protocol. These may be in the public domain, and perhaps Henry knows where to look. For a couple of weeks I'll be out of touch with my source, who may or may not a) know the numbers, or b) feel at liberty to tell. I would guess that Ligand's scientists didn't clutter the dose with a meal that would produce the same effect. A meal shouldn't be necessary for a small molecule drug, should it? Regards, Tuck